What You Need to Know About Having a Healthy Baby with Genetic Disorders Through Third-Generation IVF in Thailand

Opening: Real Consultation Scenario

▎Clinic Record A 32-year-old female, due to "beta-thalassemia carrier, planning to have healthy offspring through assisted reproduction," came for consultation. Both spouses are beta-thalassemia carriers and have already given birth to a child with intermediate thalassemia. Having learned that preimplantation genetic testing (PGT-M) is available in Thailand, she hopes to assess the feasibility and specific pathway.

Core Technical Pathway for Having Healthy Children with Genetic Disorders

For individuals with a clear genetic cause who wish to have unaffected offspring, preimplantation genetic testing (PGT) is currently the primary clinical solution. PGT includes three technical types: PGT-M (for monogenic diseases), PGT-SR (for chromosomal structural rearrangements), and PGT-A (for chromosomal aneuploidy). Some reproductive centers in Thailand have the capability to perform both PGT-M and PGT-SR simultaneously, which is the fundamental technical premise for the option of "going to Thailand for genetic disorders."

The application of PGT-M requires meeting the following conditions: the pathogenic gene is identified, the mutation site is located, and a detection probe can be established through family verification. Not all genetic diseases are suitable for PGT. For example, polygenic diseases (such as diabetes, hypertension) and genetic diseases with unidentified pathogenic genes cannot be effectively screened through PGT with current technical means.

Why Choose Overseas for PGT: The Intersection of Technology and Policy

The number of reproductive centers with PGT qualifications in China is limited, and the application for PGT has relatively strict medical indication reviews. Thailand has a more mature policy environment for PGT-M and PGT-SR, and some centers have accumulated many cases in the aspects of embryo biopsy, gene amplification, and sequencing analysis for genetic testing. However, it must be clarified that "going to Thailand" does not mean a higher success rate or more advanced technology, but rather provides an alternative path for some people who, due to policy, waiting periods, or technical throughput in China, have not been able to enter the PGT process in a timely manner.

Characteristics of reproductive centers in Thailand in the PGT field include: the ability to perform combined PGT-M and PGT-SR testing, relatively flexible timelines for post-biopsy genetic testing, and the availability of multiple platforms such as NGS or aCGH in the laboratory. However, the laboratory standards vary significantly between centers, and the quality of embryo biopsy, accuracy of genetic testing, and depth of genetic counseling directly affect the final outcome.

Clinical Evaluation: How Doctors Determine Suitability for PGT in Thailand

From a reproductive medicine perspective, doctors will evaluate according to the following steps:

• Genetic Evaluation: Confirm whether the genetic disease diagnosis is clear and whether the pathogenic gene and mutation site have been located. A confirmed genetic disease report and raw genetic testing data (such as BAM/FASTQ files) are required. Some centers require family verification to be completed.
• Fertility Evaluation: Female age, AMH, FSH, antral follicle count; male semen analysis. Age is one of the core variables affecting the success rate of the PGT cycle.
• Uterine Environment Evaluation: Uterine cavity shape, endometrial receptivity. Previous uterine surgery or endometrial lesions need to be addressed in advance.
• Infectious Disease Screening: Hepatitis B, Hepatitis C, HIV, syphilis, etc. Policies for carriers vary among Thai reproductive centers. Some positive infectious diseases may affect embryo processing and transfer arrangements.

After the evaluation, the doctor will combine the specific type of genetic disease, the patient's age and ovarian reserve, and past reproductive history to give a recommendation on whether to proceed with the PGT cycle. For older women or those with significantly diminished ovarian reserve, the risk of having no detectable embryos due to insufficient egg retrieval must be fully communicated.

Differences Between Thailand and Other Countries: Policy, Process, and Cost

The above table is only a general comparison; actual conditions may vary for each case. It is important to emphasize that some centers in Thailand rely on outsourced laboratories for probe design and family verification in PGT-M, and quality control standards need to be verified independently.

Key Details Most Easily Overlooked

In clinical cases encountered, the following details are often overlooked but directly affect the smooth progress of the PGT cycle:

• Completeness and Format of Raw Genetic Testing Data: Some patients only have printed genetic reports, lacking the raw sequencing files needed for probe design. This prevents the Thai laboratory from completing family verification or probe synthesis, requiring a new blood draw and testing, adding an extra 4-6 weeks.
• Necessity of Family Verification: PGT-M for most monogenic diseases requires DNA samples from both spouses and the proband (or parents) for linkage analysis. If the proband has passed away or cannot provide a sample, an effective testing system cannot be established for some genetic diseases.
• Staged Genetic Counseling: For PGT in Thailand, genetic counseling is usually divided into two parts: confirming the genetic disease diagnosis and carrier status in China, and designing the embryo testing plan and interpreting results at the Thai center. Information gaps often occur at the junction of these two stages. It is recommended to organize all domestic genetic materials (including raw data) and have a genetic doctor prepare a written summary before going abroad.
• Timing and Method of Embryo Biopsy: Different centers in Thailand have different practices for embryo biopsy (cleavage stage biopsy vs. blastocyst stage biopsy) and the number of cells biopsied, which can affect the success rate of subsequent genetic testing.

Common Pitfalls

Based on practitioner observations, the following are high-frequency risk points when choosing to undergo PGT in Thailand:

• Lack of Transparency from Intermediaries: Some intermediaries recommend "partner hospitals" that do not actually have PGT qualifications or meet laboratory standards, leading to failed embryo testing or inaccurate results. It is recommended to directly verify whether the hospital has JCI accreditation, an independent molecular genetics laboratory, and full-time genetic counselors.
• Insufficient Understanding of PGT Technical Limitations: Some patients believe PGT can detect all genetic diseases or that tested embryos are guaranteed to be healthy. In reality, PGT-M has limitations such as allele drop-out (ADO) and chromosomal mosaicism, and cannot rule out new mutations or non-target diseases.
• Incomplete Cost Estimates: The cost of a PGT cycle in Thailand usually includes ovarian stimulation, egg retrieval, embryo culture, biopsy, genetic testing, and frozen embryo transfer. However, fees for probe design (sometimes charged separately), re-biopsy of embryos, additional freezing, and repeat cycles due to testing failure are often not clearly listed in the initial quote.
• Legal and Ethical Risks: Thailand has clear regulations on the disposal of embryos after testing, ownership rights of remaining embryos, and sex selection (unless related to X-linked genetic diseases). Some centers may engage in boundary-crossing practices to attract clients, so caution is needed.

Actual Medical Process: From Domestic Preparation to Embryo Transfer

A complete PGT cycle in Thailand generally includes the following stages:

1. Domestic Preparation Phase (1-3 months): Complete genetic disease diagnosis and obtain raw genetic testing data; fertility evaluation for both spouses (AMH, semen analysis, infectious disease screening); uterine cavity examination (if needed); organize all medical records and have them translated and notarized.
2. Initial Consultation and Plan Formulation at Thai Center (1 visit to Thailand, approx. 3-5 days): Bring all materials for an in-person consultation with the attending physician, confirm the genetic testing plan, sign informed consent, and complete registration.
3. Ovarian Stimulation and Egg Retrieval Cycle (approx. 12-15 days): Start ovarian stimulation on day 2 of menstruation, average stimulation for 10-12 days, egg retrieval surgery on the day the male partner provides a semen sample.
4. Embryo Culture and Biopsy (5-7 days after egg retrieval): Culture embryos to the blastocyst stage, perform biopsy on trophectoderm cells of the blastocyst, and cryopreserve the embryos after biopsy.
5. Genetic Testing Phase (3-4 weeks after biopsy): Send biopsied cells for PGT-M/PGT-SR testing and receive the genetic report.
6. Frozen Embryo Transfer (1 visit to Thailand, approx. 5-8 days): Select transferable embryos based on test results, prepare the endometrium, and perform frozen embryo transfer. Pregnancy test 12-14 days after transfer.

The entire cycle spans approximately 4-6 months, including two visits to Thailand (initial consultation and egg retrieval cycle, and the transfer cycle). If no new probe design or additional family verification is needed, the time can be shortened to 3-4 months.

Frequently Asked Questions

Special Populations Requiring Extra Attention

The following situations require more careful evaluation when considering PGT in Thailand:

• Female age ≥ 38 years: Reduced egg retrieval numbers and increased embryo aneuploidy rates may lead to a situation of "no embryos to test" or "no normal embryos to transfer."
• Severely diminished ovarian reserve (AMH < 1.0 ng/mL): Assess in advance whether it is suitable to enter the cycle; consider using donor eggs if necessary.
• X-linked recessive genetic disease with the female as a carrier: PGT-M can distinguish embryo sex and carrier status, but it requires that the pathogenic gene has been located.
• Previous multiple IVF failures or low embryo development rates: First investigate egg or sperm factors before directly entering a PGT cycle.

Suggestions from a Reproductive Medicine Perspective

As a doctor long engaged in genetics and reproductive clinical work, here are a few points for reference:

• PGT is an effective means to block the vertical transmission of genetic diseases, but not the only one. Prenatal diagnosis (amniocentesis/chorionic villus sampling) combined with selective termination of pregnancy remains a widely used clinical method for blocking genetic diseases, especially for families who are not suitable for or unwilling to undergo PGT.
• Before going to Thailand for PGT, it is recommended to complete the genetic disease diagnosis and family verification for genetic testing in China first. This part is more reliably done in the genetics department of a top-tier Chinese hospital, and the cost is relatively controllable.
• There are differences in laboratory standards and genetic counseling capabilities among reproductive centers in Thailand. It is recommended not to rely on a single information source; compare the qualifications and case data of at least 2-3 centers.
• After the PGT cycle, regardless of the outcome, it is recommended to continue with prenatal diagnosis (such as amniocentesis) at a正规 hospital to verify the PGT results. This is the current standard clinical practice both domestically and internationally.

Ending: Risk Reminder